Abstract Body: Peripheral artery disease (PAD) affects more than 200 million people worldwide and ~12 million in the US. The disease is characterized by progressive narrowing of the arteries in the extremities, leading to claudication, functional decline, and severe ischemia in advanced cases. Women with PAD often present with distinct symptoms and disease progression compared with men, likely due to hormonal influences and structural vascular differences. Balloon angioplasty, the standard interventional treatment for PAD, restores blood flow by dilating a balloon within the stenosed vessel. Drug-coated balloons (DCBs) deliver an antiproliferative agent during dilation and improve vessel patency with reduced reintervention rates compared with plain balloons. However, paclitaxel, the only FDA-approved drug used in DCBs, is preloaded at a fixed dose, limiting patient-specific therapy. Here, we investigate a drug-agnostic hydrogel coating designed to enable on-demand, controlled drug loading on commercially available angioplasty balloons. To evaluate coating performance under physiologically relevant conditions, artificial models of the superficial femoral artery (SFA) were integrated into a mock circulatory loop operating under pulsatile pressures and flow rates. Four combinations of SFA diameter and stiffness were tested to reflect sex-associated vascular variability. Following several hours of circulation, the hydrogel coating remained intact and adherent to the vessel wall. To assess drug retention and release capability, the anticoagulant enoxaparin was incorporated into the hydrogel. Elution studies demonstrated sustained drug release, with concentrations remaining within physiologically active levels over time. These findings demonstrate the feasibility of a hydrogel-based coating for adaptable drug delivery during balloon angioplasty. This platform may enable patient-specific and sex-informed therapeutic strategies for PAD. Ongoing work will evaluate paclitaxel-loaded hydrogels and assess biocompatibility in preclinical animal models.